Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

ABSTRACT:

Aims

Overactive bladder (OAB) is common in men and may exist concomitantly with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population.

Methods

All participants received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on validated questionnaires, which included the single-item Patient Perception of Bladder Condition (PPBC), the King's Health Questionnaire (KHQ) and the Beck Depression Inventory-II (BDI-II).

Results

The proportion of men (n=369; mean age=69.6 years) who reported that their bladder condition caused moderat

SUBMITTER: Staskin DR 

PROVIDER: S-EPMC2228367 | biostudies-literature | 2008 Jan

REPOSITORIES: biostudies-literature